Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...101102103104105106107108109110111...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. (Pubmed Central) -  Jun 12, 2019   
    ...To test this hypothesis, we performed a screen of a representative collection of basal versus non-basal HNSCC cell lines for their sensitivity to several anti-EGFR drugs (Cetuximab, Afatinib, and Gefitinib), tested as monotherapy or in combination with drugs that target closely-linked pathways [Mitogen-activated protein kinase kinase/ extracellular signal-regulated kinases (MEK), mammalian Target of Rapamycine (mTOR) or Human Epidermal growth factor Receptor 2 (HER2)]...Strikingly, the basal-like status was found to be a better predictor of cell response to EGFR blockade than clinically relevant mutations [e.g., cyclin-dependent kinase Inhibitor 2A (CDKN2A)]. Interestingly, we show that EGFR blockade inhibits EREG expression, and that EREG knock-down decreases basal cell clonogenic survival, suggesting that EREG expression could be a predictive functional marker of sensitivity to EGFR blockade in basal-like HNSCC.
  • ||||||||||  feladilimab (GSK3359609) / GSK
    Phase classification, Combination therapy, Metastases:  GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) -  Jun 12, 2019   
    P2,  N=114, Recruiting, 
    Interestingly, we show that EGFR blockade inhibits EREG expression, and that EREG knock-down decreases basal cell clonogenic survival, suggesting that EREG expression could be a predictive functional marker of sensitivity to EGFR blockade in basal-like HNSCC. Phase classification: P1/2 --> P2
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer (clinicaltrials.gov) -  Jun 7, 2019   
    P2,  N=59, Recruiting, 
    N=261 --> 348 | Trial completion date: Jun 2019 --> May 2021 | Trial primary completion date: Feb 2019 --> May 2021 Trial completion date: May 2024 --> Dec 2023 | Trial primary completion date: May 2022 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (Pubmed Central) -  Jun 6, 2019   
    Interestingly, cetuximab-mediated immunogenicity through antibody dependent cell cytotoxicity (ADCC) has encouraged the evaluation of combined approaches with immune-checkpoint inhibitors in both LA and R/M-HNSCC settings. This article reviews the accumulated evidence on the role of cetuximab in HNSCC in the past decade, offering an overview of its current impact in the treatment of LA and R/M-HNSCC disease and its potential use in the era of immunotherapy.
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment open, Metastases:  Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer (clinicaltrials.gov) -  Jun 4, 2019   
    P2,  N=59, Recruiting, 
    The assessment of HGPs should be further explored as a predictor of benefit from available targeted agents. Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Observational data, Journal, Adverse events:  Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. (Pubmed Central) -  Jun 3, 2019   
    Papulopustular eruptions were seen in 61 (80.2%) patients, xerosis in 31 (40.7%), mucositis in 6 (7.8%), hair growth problems in 4 (5.6%), and paronychia and pyogenic granuloma in 2 (2.6%) patients each. Although most of the skin toxicities associated with EGFR inhibitors can be managed conservatively, a critical analysis of the cases that are significantly affected due to these side effects is required in cohesion with the treating oncologist to improve the therapeutic compliance of the drug.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Review, Journal:  Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis. (Pubmed Central) -  May 30, 2019   
    The results support the potential role of exosomes as a non-invasive tumor and immune cell biomarkers in cancer. ETS is a simple and interesting intermediate endpoint for clinical practice and future trials of medical treatments of patients with mCRC, but a large prospective analysis and validation are mandatory.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Clinical, Journal:  A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. (Pubmed Central) -  May 29, 2019   
    We report a case of an 83-year-old Hispanic man, non-smoker, with KRAS/NRAS wild-type mCRC of the liver who was treated with 9 cycles of FOLFOX4 (fluorouracil, leucovorin and oxaliplatin) and cetuximab...We aim to highlight the risk of severe life-threatening ILD associated with panitumumab. Early recognition of this serious adverse event helps avoid unnecessary administration of systemic antibiotics and prevent mortality.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
    Trial completion date, Metastases:  Regorafenib and Cetuximab in Patients With Advanced Malignancy (clinicaltrials.gov) -  May 29, 2019   
    P1,  N=39, Active, not recruiting, 
    Trial completion date: Feb 2019 --> Mar 2024 | Trial primary completion date: Feb 2019 --> Mar 2024 Trial completion date: Mar 2023 --> Mar 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. (Pubmed Central) -  May 24, 2019   
    P3
    These SNPs did not overlap with SNPs associated with cetuximab efficacy as found in a previous GWAS in the same CAIRO2 cohort. If formally proven by replication, the SNPs associated with severe EGFR induced skin toxicity may be helpful to predict the occurrence and severity of skin toxicity in patients that will receive cetuximab and allow for adequate information on the risk of skin toxicity and prophylactic measurements.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Metastases:  TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer. (clinicaltrials.gov) -  May 24, 2019   
    P3,  N=519, Completed, 
    If formally proven by replication, the SNPs associated with severe EGFR induced skin toxicity may be helpful to predict the occurrence and severity of skin toxicity in patients that will receive cetuximab and allow for adequate information on the risk of skin toxicity and prophylactic measurements. Recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma. (Pubmed Central) -  May 21, 2019   
    Furthermore, Met was highly expressed in OSCC tissues and associated with a poor patient survival, while Met/HGF-activated Akt also was associated with a poor patient survival. This study demonstrates that Met/HGF expression results in OSCC resistance to cetuximab and tumor recurrence after cetuximab therapy; thus, inhibition of Met/HGF activity could restore OSCC sensitivity to cetuximab.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  RTOG-1016: Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer (clinicaltrials.gov) -  May 20, 2019   
    P3,  N=987, Active, not recruiting, 
    This study demonstrates that Met/HGF expression results in OSCC resistance to cetuximab and tumor recurrence after cetuximab therapy; thus, inhibition of Met/HGF activity could restore OSCC sensitivity to cetuximab. Trial completion date: Jun 2024 --> Jul 2023 | Trial primary completion date: Jun 2020 --> Jul 2018
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon Cancer Cell Cultures. (Pubmed Central) -  May 17, 2019   
    The developed method was also been applied to map cetuximab distribution in patient-derived colorectal tumor organoids (CTOs). Overall, we believe this powerful label-free approach will be useful to visualize the heterogeneous distribution of antibody drugs in tissues and tumors, and help to monitor and optimize their use in the clinic.
  • ||||||||||  Enrollment closed, Metastases:  QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) -  May 17, 2019   
    P1b/2,  N=332, Active, not recruiting, 
    Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2021 Recruiting --> Active, not recruiting